BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 38494294)

  • 21. Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review.
    Braik T; Evans AT; Telfer M; McDunn S
    Am J Med Sci; 2010 Oct; 340(4):301-8. PubMed ID: 20460982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review.
    Khouri J; Nakashima M; Wong S
    JAMA Oncol; 2021 Sep; 7(9):1383-1391. PubMed ID: 34081097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging Review of Paraneoplastic Neurologic Syndromes.
    Madhavan AA; Carr CM; Morris PP; Flanagan EP; Kotsenas AL; Hunt CH; Eckel LJ; Lindell EP; Diehn FE
    AJNR Am J Neuroradiol; 2020 Dec; 41(12):2176-2187. PubMed ID: 33093137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraneoplastic neurological syndromes.
    Graus F; Dalmau J
    Curr Opin Neurol; 2012 Dec; 25(6):795-801. PubMed ID: 23041955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paraneoplastic antibodies targeting intracellular antigens.
    Linnoila JJ
    Handb Clin Neurol; 2024; 200():335-346. PubMed ID: 38494288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes.
    Blaes F
    Expert Rev Neurother; 2021 Jun; 21(6):675-686. PubMed ID: 33960258
    [No Abstract]   [Full Text] [Related]  

  • 28. [Paraneoplastic neurological syndromes and autoimmune encephalitis].
    Stich O; Rauer S
    Nervenarzt; 2014 Apr; 85(4):485-98; quiz 499-501. PubMed ID: 24668402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pathology of paraneoplastic syndromes of the central and peripheral nervous systems and muscle ].
    Ferrer I
    Rev Neurol; 2000 Dec 16-31; 31(12):1228-36. PubMed ID: 11211860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paraneoplastic cerebellar and brainstem disorders.
    Abbatemarco JR; Vedeler CA; Greenlee JE
    Handb Clin Neurol; 2024; 200():173-191. PubMed ID: 38494276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paraneoplastic neurological syndromes.
    Honnorat J; Antoine JC
    Orphanet J Rare Dis; 2007 May; 2():22. PubMed ID: 17480225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
    Dispenzieri A
    Am J Hematol; 2019 Jul; 94(7):812-827. PubMed ID: 31012139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on neurological paraneoplastic syndromes.
    Höftberger R; Rosenfeld MR; Dalmau J
    Curr Opin Oncol; 2015 Nov; 27(6):489-95. PubMed ID: 26335665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Paraneoplastic cerebral syndromes with oto-neuro-ophthalomologic manifestations].
    Dalmau J; Porta-Etessam J
    Rev Neurol; 2000 Dec 16-31; 31(12):1213-9. PubMed ID: 11205562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraneoplastic disorders of the central and peripheral nervous systems.
    Didelot A; Honnorat J
    Handb Clin Neurol; 2014; 121():1159-79. PubMed ID: 24365410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical approach to diagnosis of paraneoplastic neurologic syndromes.
    Graus F
    Handb Clin Neurol; 2024; 200():79-96. PubMed ID: 38494298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paraneoplastic neuropathies.
    Graus F; Dalmau J
    Curr Opin Neurol; 2013 Oct; 26(5):489-95. PubMed ID: 23892629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. POEMS syndrome: update on diagnosis, risk-stratification, and management.
    Dispenzieri A
    Am J Hematol; 2015 Oct; 90(10):951-62. PubMed ID: 26331353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Crow-Fukase (POEMS) syndrome].
    Kuwabara S
    Brain Nerve; 2010 Apr; 62(4):395-400. PubMed ID: 20420180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [POEMS syndrome: monoclonal plasma cell disorder with polyneuropathy].
    Kamezaki K; Nagafuji K
    Nihon Rinsho; 2007 Dec; 65(12):2235-7. PubMed ID: 18069266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.